NCT02926690
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02926690
Title Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OncoTherapy Science, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Norwalk Hospital COMPLETED Norwalk Connecticut 06856 United States Details
Emory University, Winship Cancer Institute NOT_YET_RECRUITING Atlanta Georgia 30322 United States Details
Kapi'olani Medical Center for Women & Children RECRUITING Honolulu Hawaii 96826 United States Details
Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center RECRUITING Lebanon New Hampshire 03756 United States Details
Weill Cornell Medicine | NewYork-Presbyterian COMPLETED New York New York 10065 United States Details
Memorial Sloan Kettering Cancer Center COMPLETED New York New York 11065 United States Details
MD Anderson Cancer Center COMPLETED Houston Texas 77030 United States Details
Froedtert Hospital & the Medical College of Wisconsin NOT_YET_RECRUITING Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field